995:'s Lovaza, which was approved in 2004.) Initial sales were not as robust as Amarin had hoped. The labels for the two drugs were similar, but doctors prescribed Lovaza for people who had triglycerides lower than 500 mg/dL based on some clinical evidence. Amarin wanted to actively market E-EPA for that population as well which would have greatly expanded its revenue and applied to the FDA for permission to do so in 2013, which the FDA denied. In response, in May 2015 Amarin sued the FDA for infringing its
627:
36:
105:
3188:
1293:
886:
such as people who have diabetes. Compared to dietary supplements, the ingredients in prescription drugs are more carefully controlled and are typically fixed and tested in clinical trials. The prescription forms are also typically more concentrated, requiring fewer capsules to be taken and increasing the likelihood of compliance.
1010:
The efficacy and safety of icosapent ethyl were established in a study with 8,179 participants who were either 45 years and older with a documented history of coronary artery, cerebrovascular, carotid artery and peripheral artery disease or 50 years and older with diabetes and additional risk factors
999:
rights, and in August 2015, a judge ruled that the FDA could not "prohibit the truthful promotion of a drug for unapproved uses because doing so would violate the protection of free speech." The ruling left open the question of what the FDA would allow Amarin to say about E-EPA, and in March 2016 the
885:
Ethyl eicosapentaenoic acid is a prescription medication in the US, but it closely resembles other marine based omega−3 dietary supplements. Evidence suggests that these supplements are able to reduce cardiovascular disease, and premature death. These effects may not carry over in other populations
914:
After ingestion, ethyl eicosapentaenoic acid (E-EPA) is metabolized to eicosapentaenoic acid (EPA). EPA is absorbed in the small intestine and enters circulation. Peak plasma concentration occurs about five hours after ingestion, and the half-life is about 89 hours. EPA is lipolyzed mostly in the
854:
values (most typically only a calculated estimate and not measured by labs from person's blood sample for technical and cost reasons; however, this is accurately calculated with a less common NMR lipid panel lab), whilst eicosapentaenoic acid (EPA) alone does not and instead lowers the parameters
837:
In the United States, icosapent ethyl is indicated as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adults with elevated triglyceride levels (≥ 150 mg/dL) and
1014:
In clinical trials, icosapent ethyl was associated with an increased risk of atrial fibrillation or atrial flutter (irregular heart rhythms) requiring hospitalization. The incidence of atrial fibrillation was greater among participants with a history of atrial fibrillation or atrial flutter.
841:
Intake of large doses (2.0 to 4.0 g/day) of long-chain omega−3 fatty acids as prescription drugs or dietary supplements are generally required to achieve significant (> 15%) lowering of triglycerides, and at those doses the effects can be significant (from 20% to 35% and even up to 45% in
1003:
In
December 2019, the FDA approved the use of icosapent ethyl as an adjunctive (secondary) therapy to reduce the risk of cardiovascular events among adults with elevated triglyceride levels (a type of fat in the blood) of 150 milligrams per deciliter or higher. People must also have either
810:-based medication after omega-3-acid ethyl esters (brand named Lovaza, itself approved in 2004). On 13 December 2019, the FDA also approved Vascepa as the first drug specifically "to reduce cardiovascular risk among people with elevated triglyceride levels". It is available as a
1015:
Icosapent ethyl was also associated with an increased risk of bleeding events. The incidence of bleeding was higher among participants who were also taking other medications that increase the risk of bleeding, such as aspirin, clopidogrel or warfarin at the same time.
1032:(EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vazkepa, intended to reduce the risk of cardiovascular events in people at high cardiovascular risk. The applicant for this medicinal product is
906:. The most commonly reported side effect in clinical trials has been joint pain; some people also reported pain in their mouth or throat. E-EPA has not been tested in pregnant women; it is excreted in breast milk and the effects on infants are not known.
923:
Eicosapentaenoic acid (EPA), the active metabolite of ethyl eicosapentaenoic acid (E-EPA), like other omega−3 fatty acid based drugs, appears to reduce production of triglycerides in the liver and to enhance clearance of triglycerides from circulating
1000:
FDA and Amarin agreed that Amarin would submit specific marketing material to the FDA for the FDA to review (as is usual for prescription medications). If the parties disagreed on whether the material was truthful, they would seek a judge to mediate.
838:
established cardiovascular disease or diabetes and two or more additional risk factors for cardiovascular disease. It is also indicated as an adjunct to diet to reduce triglyceride levels in adults with severe (≥ 500 mg/dL) hypertriglyceridemia.
791:
The most common side effects are musculoskeletal pain, peripheral edema (swelling of legs and hands), atrial fibrillation, and arthralgia (joint pain). Other common side effects include bleeding, constipation, gout, and rash.
1668:
1278:
2246:
1318:
326:
842:
individuals with levels greater that 500 mg/dL). It appears that both eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) lower triglycerides; however, DHA alone appears to raise
788:. It is used in combination with changes in diet in adults with hypertriglyceridemia ≥ 150 mg/dL. Further, it is often required to be used with a statin (maximally-tolerated dose).
2312:
1714:
2345:
2279:
229:
1096:
290:
2219:
752:
1692:
1382:
1007:
Icosapent ethyl is the first FDA approved drug to reduce cardiovascular risk among people with elevated triglyceride levels as an add-on to maximally tolerated statin therapy.
2134:
2160:
1011:
for cardiovascular disease. Participants who received icosapent ethyl were significantly less likely to experience a cardiovascular event, such as a stroke or heart attack.
1956:"American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease"
1643:
1266:
1147:
736:
InChI=1S/C22H34O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24-4-2/h5-6,8-9,11-12,14-15,17-18H,3-4,7,10,13,16,19-21H2,1-2H3/b6-5-,9-8-,12-11-,15-14-,18-17-
1664:
46:
2421:
195:
2236:
144:
1756:
708:
2109:
1348:
2194:
1810:"Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127 477 Participants"
3088:
1219:
2673:
2381:
3208:
3233:
2302:
3142:
2335:
1722:
2414:
2269:
2045:
1189:
1086:
2216:
1684:
1370:
728:
225:
80:
2131:
694:
2152:
2452:
1442:
58:
1635:
1139:
1004:
established cardiovascular disease alone or diabetes along with two or more additional risk factors for cardiovascular disease.
2407:
377:
311:
176:
1609:
1412:
1064:
2075:
1610:"University of Utah Pharmacy Services (15 August 2007) "Omega-3-acid Ethyl Esters Brand Name Changed from Omacor to Lovaza""
212:
3243:
1906:
3178:
2677:
2443:
2188:
2103:
1997:"Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association"
1786:
1750:
1376:
1272:
969:
925:
803:
519:
3159:
980:
had developed the drug. Amarin
Corporation challenged the FDA's authority to limit its ability to market the drug for
933:
606:
62:
1744:
898:. In addition, as with other omega−3 fatty acids, taking ethyl eicosapentaenoic acid (E-EPA) puts people who are on
3223:
131:
130:
Eicosapentaenoic acid ethyl ester; Ethyl eicosapentaenoate; Eicosapent; EPA ethyl ester; E-EPA, Icosapent ethyl (
3103:
2375:
2097:
1183:
1029:
988:
867:
190:
3002:
2968:
2883:
2625:
1515:
Weintraub HS (November 2014). "Overview of prescription omega-3 fatty acid products for hypertriglyceridemia".
873:
468:
1995:
Skulas-Ray AC, Wilson PW, Harris WS, Brinton EA, Kris-Etherton PM, Richter CK, et al. (September 2019).
3147:
3027:
3022:
2997:
2964:
2926:
2710:
2629:
2565:
2492:
2182:
863:
There are other omega−3 fish-oil based drugs on the market that have similar uses and mechanisms of action:
843:
266:
1954:
Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al. (April 2017).
3238:
3012:
3007:
2156:
1468:
1211:
1033:
595:
2794:
2370:
2215:
VHA Pharmacy
Benefits Management Strategic Healthcare Group and the Medical Advisory Panel. October 2005
3218:
3213:
3017:
2484:
953:
827:
799:
459:
814:. In 2020, it was the 285th most commonly prescribed medication in the United States, with more than 1
806:(FDA) granted the approval of icosapent ethyl in 2012 to Amarin Corporation, and it became the second
3228:
3058:
2784:
2643:
973:
785:
622:
1473:"National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2"
984:
and won its case on appeal in 2012, changing the way the FDA regulates the marketing of medication.
2430:
414:
273:
1267:"FDA approves use of drug to reduce risk of cardiovascular events in certain adult patient groups"
3042:
2488:
2340:
2307:
2274:
1560:"Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA)"
1540:
977:
957:
937:
811:
796:
240:
1859:"Blood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies"
928:(VLDL) particles. The way it does that is not clear, but potential mechanisms include increased
3037:
2706:
2663:
2561:
2018:
1977:
1936:
1888:
1839:
1591:
1532:
1494:
1340:
575:
350:
338:
117:
936:, which is involved in biosynthesis of triglycerides in the liver; and increased activity of
508:
2037:
2008:
1967:
1926:
1878:
1870:
1829:
1821:
1581:
1571:
1524:
1484:
1330:
1178:
643:
96:
528:
423:
3192:
2922:
2738:
2223:
2138:
1672:
996:
992:
1857:
Harris WS, Tintle NL, Imamura F, Qian F, Korat AV, Marklund M, et al. (April 2021).
626:
104:
3153:
2879:
2719:
1883:
1858:
1834:
1809:
1586:
1335:
987:
Ethyl eicosapentaenoic acid (E-EPA) was the second fish-oil drug to be approved, after
929:
899:
154:
1434:
1036:
Ireland
Limited. It was approved for medical use in the European Union in March 2021.
3202:
2526:
2516:
1297:
1091:
1028:
On 28 January 2021, the
Committee for Medicinal Products for Human Use (CHMP) of the
981:
903:
168:
1544:
448:
3128:
2804:
2799:
2766:
2757:
2729:
2658:
2609:
2599:
2579:
2574:
2434:
1613:
895:
781:
1404:
1056:
2067:
2013:
1996:
3108:
3083:
3063:
3032:
2940:
2912:
2907:
2902:
2897:
2892:
2844:
2839:
2829:
2824:
2789:
2696:
2686:
2614:
2604:
2584:
2534:
2501:
194:
162:
2217:
National PBM Drug
Monograph Omega-3-acid ethyl esters (Lovaza, formerly Omacor)
1874:
1489:
1472:
3123:
3098:
3078:
3073:
3068:
2977:
2950:
2945:
2935:
2849:
2819:
2814:
2809:
2743:
2691:
2653:
2594:
2589:
2511:
2506:
2469:
2399:
1576:
1559:
777:
670:
499:
280:
1778:
1528:
2834:
2521:
2474:
2464:
2237:"Why The FDA Is Right To Block Amarin's Push To Market Fish Oil To Millions"
1911:"5. Facilitating Behavior Change and Well-being to Improve Health Outcomes:
1825:
148:
2022:
1981:
1972:
1955:
1940:
1892:
1843:
1595:
1536:
1498:
1344:
3118:
3113:
3093:
2865:
2638:
2530:
807:
479:
207:
17:
876:(Epanova); the Epanova brand name was discontinued in the United States.
488:
2960:
2776:
2183:"Drug Approval Package: Omacor (Omega-3-Acid Ethyl Esters) NDA #021654"
434:
1931:
1910:
2648:
2557:
2456:
2241:
831:
586:
1319:"A Comparative Overview of Prescription Omega-3 Fatty Acid Products"
555:
548:
2548:
949:
870:(brand names Omacor ), and as of March 2016, four generic versions
851:
693:
684:
566:
1296:
This article incorporates text from this source, which is in the
539:
356:
185:
2403:
2365:
2363:
2303:"Court Forbids F.D.A. From Blocking Truthful Promotion of Drug"
344:
219:
202:
2098:"Drug Approval Package: Vascepa (icosapent ethyl) NDA #202057"
972:(FDA) approved ethyl eicosapentaenoic acid (E-EPA) for severe
29:
2336:"F.D.A. Deal Allows Amarin to Promote Drug for Off-Label Use"
45:
deal primarily with the United States and do not represent a
2270:"Drugmaker Sues F.D.A. Over Right to Discuss Off-Label Uses"
611:
1745:"Drug Approval Package: Epanova (Omega-3-carboxylic acids)"
320:
251:
1779:"Epanova (omega-3-carboxylic acids) FDA Approval History"
333:
54:
3176:
894:
Special caution should be taken with people who have
846:(the variant which drives atherosclerosis; sometimes
2007:(12). Lippincott Williams & Wilkins: e673–e691.
1134:
3051:
2990:
2959:
2921:
2878:
2858:
2775:
2765:
2756:
2728:
2705:
2672:
2623:
2556:
2547:
2483:
2451:
2442:
2153:"Health Law Case Brief: Amarin Pharma, Inc. v. FDA"
1925:(Suppl 1). American Diabetes Association: S48–S65.
1132:
1130:
1128:
1126:
1124:
1122:
1120:
1118:
1116:
1114:
682:
669:
642:
637:
605:
585:
565:
538:
518:
498:
478:
467:
458:
433:
413:
368:
310:
305:
289:
279:
265:
239:
175:
161:
143:
126:
116:
111:
1312:
1310:
1308:
1306:
948:Ethyl eicosapentaenoic acid (E-EPA) is an ethyl
447:
1051:
1049:
830:to reduce cardiovascular risk as an adjunct to
422:
2036:Sweeney ME (14 April 2015). Khardori R (ed.).
1462:
1460:
1173:
1171:
1169:
1167:
1165:
224:
2415:
1467:Jacobson TA, Maki KC, Orringer CE, Jones PH,
1087:"Summary Basis of Decision (SBD) for Vascepa"
43:The examples and perspective in this article
8:
2038:"Hypertriglyceridemia Pharmacologic Therapy"
211:
95:
1636:"Omtryg- omega-3-acid ethyl esters capsule"
2772:
2762:
2553:
2448:
2422:
2408:
2400:
2068:"Icosapent (Vascepa) Use During Pregnancy"
1913:Standards of Medical Care in Diabetes-2020
1510:
1508:
826:In the European Union, icosapent ethyl is
625:
507:
3089:Magnesium pyridoxal 5-phosphate glutamate
2012:
1971:
1930:
1882:
1833:
1814:Journal of the American Heart Association
1585:
1575:
1488:
1435:"Icosapent Ethyl - Drug Usage Statistics"
1334:
1261:
1259:
1257:
527:
81:Learn how and when to remove this message
1255:
1253:
1251:
1249:
1247:
1245:
1243:
1241:
1239:
1237:
3183:
1808:Hu Y, Hu FB, Manson JE (October 2019).
1045:
733:
713:
621:
487:
382:
167:
1665:FDA Omega-3 acid ethyl esters products
1445:from the original on 27 September 2022
1061:Therapeutic Goods Administration (TGA)
94:
2315:from the original on 22 December 2020
2282:from the original on 22 December 2020
2078:from the original on 22 December 2019
1558:Brinton EA, Mason RP (January 2017).
1371:"Icosapent ethyl: FDA-Approved Drugs"
1281:from the original on 22 December 2019
594:
574:
153:
135:
7:
2384:from the original on 1 February 2021
2348:from the original on 8 November 2020
2249:from the original on 2 December 2020
2197:from the original on 2 February 2020
2163:from the original on 31 October 2021
2112:from the original on 15 January 2020
1789:from the original on 16 January 2020
1759:from the original on 15 January 2020
1715:"Epanova (omega-3-carboxylic acids)"
1695:from the original on 2 February 2020
1646:from the original on 11 January 2017
1385:from the original on 19 October 2020
1216:Union Register of medicinal products
1150:from the original on 5 February 2021
1067:from the original on 5 February 2023
1277:(Press release). 13 December 2019.
976:as an adjunct to dietary measures;
554:
547:
438:
1415:from the original on 18 March 2020
1140:"Vascepa- icosapent ethyl capsule"
25:
2453:Cholesterol absorption inhibitors
2048:from the original on 8 April 2018
1222:from the original on 5 March 2023
3186:
1471:, Sikand G, et al. (2015).
1291:
1192:from the original on 9 July 2021
1099:from the original on 31 May 2022
716:CCC=CCC=CCC=CCC=CCC=CCCCC(=O)OCC
654:
405:)-icosa-5,8,11,14,17-pentaenoate
103:
34:
741:Key:SSQPWTVBQMWLSZ-AAQCHOMXSA-N
3209:Drugs not assigned an ATC code
2371:"Vazkepa: Pending EC decision"
1477:Journal of Clinical Lipidology
850:called "bad cholesterol") and
660:
648:
1:
3234:Treatment of bipolar disorder
2042:Medscape Drugs & Diseases
1907:American Diabetes Association
1212:"Vazkepa Product information"
772:), sold under the brand name
2235:Herper M (17 October 2013).
2189:Food and Drug Administration
2104:Food and Drug Administration
2014:10.1161/CIR.0000000000000709
1751:Food and Drug Administration
1667:Page accessed 31 March 2016
1377:Food and Drug Administration
1273:Food and Drug Administration
970:Food and Drug Administration
926:very low-density lipoprotein
896:fish and shellfish allergies
804:Food and Drug Administration
2301:Pollack A (7 August 2015).
2151:Mariani E (28 March 2016).
2141:Page accessed 31 March 2016
1685:"Omega-3-acid ethyl esters"
934:diglyceride acyltransferase
762:Ethyl eicosapentaenoic acid
97:Ethyl eicosapentaenoic acid
57:, discuss the issue on the
3260:
1966:(Suppl 2). AACECOR: 1–87.
1875:10.1038/s41467-021-22370-2
1490:10.1016/j.jacl.2015.09.002
859:Other fish-oil based drugs
638:Chemical and physical data
3137:
3104:Omega−3-acid ethyl esters
2376:European Medicines Agency
2334:Thomas K (9 March 2016).
2132:Vascepa (icosapent ethyl)
1577:10.1186/s12944-017-0415-8
1184:European Medicines Agency
1030:European Medicines Agency
989:omega-3-acid ethyl esters
868:Omega-3-acid ethyl esters
749:
724:
704:
373:
102:
3003:Bempedoic acid/ezetimibe
2624:Niacin and derivatives (
2222:22 December 2016 at the
1671:5 September 2015 at the
1529:10.3810/pgm.2014.11.2828
1317:Ito MK (December 2015).
930:breakdown of fatty acids
874:Omega-3-carboxylic acids
3028:Fenofibrate/simvastatin
3023:Fenofibrate/pravastatin
2998:Amlodipine/atorvastatin
2268:Thomas K (7 May 2015).
1826:10.1161/JAHA.119.013543
844:low-density lipoprotein
818:million prescriptions.
3013:Ezetimibe/rosuvastatin
3008:Ezetimibe/atorvastatin
2485:Bile acid sequestrants
2157:Boston Bar Association
1973:10.4158/EP171764.APPGL
1483:(6 Suppl): S1–122.e1.
1034:Amarin Pharmaceuticals
902:at risk for prolonged
3018:Ezetimibe/simvastatin
2431:Lipid-lowering agents
2137:5 August 2019 at the
1863:Nature Communications
1517:Postgraduate Medicine
1405:"The Top 300 of 2020"
968:In July 2012, the US
954:eicosapentaenoic acid
800:eicosapentaenoic acid
3244:Hypolipidemic agents
3059:Alipogene tiparvovec
2785:Aluminium clofibrate
2644:Aluminium nicotinate
2193:. 24 December 1999.
2074:. 18 February 2019.
1146:. 23 December 2019.
1063:. 22 November 2022.
974:hypertriglyceridemia
795:It is made from the
786:hypertriglyceridemia
63:create a new article
55:improve this article
2795:Choline fenofibrate
2380:. 29 January 2021.
1725:on 25 December 2014
1188:. 25 January 2021.
1095:. 23 October 2014.
1019:Society and culture
919:Mechanism of action
776:among others, is a
329:(Prescription only)
99:
3164:Never to phase III
3043:Niacin/simvastatin
3033:Niacin/laropiprant
2341:The New York Times
2308:The New York Times
2275:The New York Times
1960:Endocrine Practice
1351:on 16 January 2020
978:Amarin Corporation
958:omega−3 fatty acid
938:lipoprotein lipase
812:generic medication
797:omega−3 fatty acid
285:Antilipemic Agents
3224:Fatty acid esters
3174:
3173:
3038:Niacin/lovastatin
2986:
2985:
2874:
2873:
2752:
2751:
2707:ATP citrate lyase
2664:Nicotinyl alcohol
2562:HMG-CoA reductase
2543:
2542:
1932:10.2337/dc20-S005
1755:. 28 March 2016.
1642:. 31 March 2016.
1564:Lipids Health Dis
848:very inaccurately
759:
758:
695:Interactive image
607:CompTox Dashboard
360:
348:
336:
324:
255:
222:
205:
188:
138:
91:
90:
83:
65:, as appropriate.
16:(Redirected from
3251:
3191:
3190:
3189:
3182:
2923:PCSK9 inhibitors
2773:
2763:
2554:
2449:
2424:
2417:
2410:
2401:
2394:
2393:
2391:
2389:
2367:
2358:
2357:
2355:
2353:
2331:
2325:
2324:
2322:
2320:
2298:
2292:
2291:
2289:
2287:
2265:
2259:
2258:
2256:
2254:
2232:
2226:
2213:
2207:
2206:
2204:
2202:
2179:
2173:
2172:
2170:
2168:
2148:
2142:
2128:
2122:
2121:
2119:
2117:
2108:. 6 March 2013.
2094:
2088:
2087:
2085:
2083:
2064:
2058:
2057:
2055:
2053:
2033:
2027:
2026:
2016:
1992:
1986:
1985:
1975:
1951:
1945:
1944:
1934:
1909:(January 2020).
1903:
1897:
1896:
1886:
1854:
1848:
1847:
1837:
1805:
1799:
1798:
1796:
1794:
1775:
1769:
1768:
1766:
1764:
1741:
1735:
1734:
1732:
1730:
1721:. Archived from
1711:
1705:
1704:
1702:
1700:
1681:
1675:
1662:
1656:
1655:
1653:
1651:
1632:
1626:
1625:
1623:
1621:
1612:. Archived from
1606:
1600:
1599:
1589:
1579:
1555:
1549:
1548:
1512:
1503:
1502:
1492:
1464:
1455:
1454:
1452:
1450:
1431:
1425:
1424:
1422:
1420:
1401:
1395:
1394:
1392:
1390:
1367:
1361:
1360:
1358:
1356:
1347:. Archived from
1338:
1314:
1301:
1295:
1294:
1290:
1288:
1286:
1263:
1232:
1231:
1229:
1227:
1208:
1202:
1201:
1199:
1197:
1175:
1160:
1159:
1157:
1155:
1136:
1109:
1108:
1106:
1104:
1083:
1077:
1076:
1074:
1072:
1053:
932:; inhibition of
855:aforementioned.
849:
817:
755:
697:
677:
662:
656:
650:
630:
629:
615:
613:
598:
578:
558:
551:
531:
511:
491:
471:
451:
441:
440:
426:
358:
355:
346:
343:
335:
332:
322:
319:
253:
250:
232:
221:
218:
215:
204:
201:
198:
187:
184:
171:
157:
137:
134:
122:Vascepa, Vazkepa
107:
100:
98:
86:
79:
75:
72:
66:
38:
37:
30:
21:
3259:
3258:
3254:
3253:
3252:
3250:
3249:
3248:
3199:
3198:
3197:
3187:
3185:
3177:
3175:
3170:
3169:
3154:Clinical trials
3133:
3047:
2982:
2955:
2917:
2880:CETP inhibitors
2870:
2854:
2748:
2739:Dextrothyroxine
2724:
2701:
2668:
2619:
2539:
2479:
2438:
2428:
2398:
2397:
2387:
2385:
2369:
2368:
2361:
2351:
2349:
2333:
2332:
2328:
2318:
2316:
2300:
2299:
2295:
2285:
2283:
2267:
2266:
2262:
2252:
2250:
2234:
2233:
2229:
2224:Wayback Machine
2214:
2210:
2200:
2198:
2181:
2180:
2176:
2166:
2164:
2150:
2149:
2145:
2139:Wayback Machine
2129:
2125:
2115:
2113:
2096:
2095:
2091:
2081:
2079:
2066:
2065:
2061:
2051:
2049:
2035:
2034:
2030:
1994:
1993:
1989:
1953:
1952:
1948:
1905:
1904:
1900:
1856:
1855:
1851:
1820:(19): e013543.
1807:
1806:
1802:
1792:
1790:
1777:
1776:
1772:
1762:
1760:
1743:
1742:
1738:
1728:
1726:
1713:
1712:
1708:
1698:
1696:
1683:
1682:
1678:
1673:Wayback Machine
1663:
1659:
1649:
1647:
1634:
1633:
1629:
1619:
1617:
1616:on 3 March 2016
1608:
1607:
1603:
1557:
1556:
1552:
1514:
1513:
1506:
1469:Kris-Etherton P
1466:
1465:
1458:
1448:
1446:
1433:
1432:
1428:
1418:
1416:
1403:
1402:
1398:
1388:
1386:
1369:
1368:
1364:
1354:
1352:
1329:(12): 826–857.
1316:
1315:
1304:
1292:
1284:
1282:
1265:
1264:
1235:
1225:
1223:
1210:
1209:
1205:
1195:
1193:
1177:
1176:
1163:
1153:
1151:
1138:
1137:
1112:
1102:
1100:
1085:
1084:
1080:
1070:
1068:
1055:
1054:
1047:
1042:
1026:
1021:
997:First Amendment
993:GlaxoSmithKline
966:
946:
921:
912:
892:
883:
861:
847:
824:
815:
770:icosapent ethyl
753:(what is this?)
750:
745:
742:
737:
732:
731:
720:
717:
712:
711:
700:
675:
665:
659:
653:
633:
623:DTXSID601018686
609:
601:
581:
561:
534:
514:
494:
474:
454:
437:
429:
409:
406:
381:
380:
364:
301:
268:
261:
242:
235:
213:Icosapent_ethyl
87:
76:
70:
67:
52:
39:
35:
28:
23:
22:
15:
12:
11:
5:
3257:
3255:
3247:
3246:
3241:
3236:
3231:
3226:
3221:
3216:
3211:
3201:
3200:
3196:
3195:
3172:
3171:
3168:
3167:
3166:
3165:
3162:
3151:
3145:
3139:
3138:
3135:
3134:
3132:
3131:
3126:
3121:
3116:
3111:
3106:
3101:
3096:
3091:
3086:
3081:
3076:
3071:
3066:
3061:
3055:
3053:
3049:
3048:
3046:
3045:
3040:
3035:
3030:
3025:
3020:
3015:
3010:
3005:
3000:
2994:
2992:
2988:
2987:
2984:
2983:
2981:
2980:
2974:
2972:
2957:
2956:
2954:
2953:
2948:
2943:
2938:
2932:
2930:
2919:
2918:
2916:
2915:
2910:
2905:
2900:
2895:
2889:
2887:
2876:
2875:
2872:
2871:
2869:
2868:
2862:
2860:
2856:
2855:
2853:
2852:
2847:
2842:
2837:
2832:
2827:
2822:
2817:
2812:
2807:
2802:
2797:
2792:
2787:
2781:
2779:
2770:
2760:
2754:
2753:
2750:
2749:
2747:
2746:
2741:
2735:
2733:
2726:
2725:
2723:
2722:
2720:Bempedoic acid
2716:
2714:
2703:
2702:
2700:
2699:
2694:
2689:
2683:
2681:
2670:
2669:
2667:
2666:
2661:
2656:
2651:
2646:
2641:
2635:
2633:
2621:
2620:
2618:
2617:
2612:
2607:
2602:
2597:
2592:
2587:
2582:
2577:
2571:
2569:
2551:
2545:
2544:
2541:
2540:
2538:
2537:
2524:
2519:
2514:
2509:
2504:
2498:
2496:
2481:
2480:
2478:
2477:
2472:
2467:
2461:
2459:
2446:
2440:
2439:
2429:
2427:
2426:
2419:
2412:
2404:
2396:
2395:
2359:
2326:
2293:
2260:
2227:
2208:
2174:
2143:
2123:
2089:
2059:
2028:
1987:
1946:
1898:
1849:
1800:
1785:. 5 May 2014.
1770:
1736:
1706:
1676:
1657:
1627:
1601:
1550:
1504:
1456:
1426:
1396:
1362:
1302:
1233:
1203:
1179:"Vazkepa EPAR"
1161:
1110:
1078:
1044:
1043:
1041:
1038:
1025:
1022:
1020:
1017:
965:
962:
956:, which is an
945:
942:
920:
917:
911:
908:
900:anticoagulants
891:
888:
882:
879:
878:
877:
871:
860:
857:
823:
820:
802:(EPA). The US
780:used to treat
757:
756:
747:
746:
744:
743:
740:
738:
735:
727:
726:
725:
722:
721:
719:
718:
715:
707:
706:
705:
702:
701:
699:
698:
690:
688:
680:
679:
673:
667:
666:
663:
657:
651:
646:
640:
639:
635:
634:
632:
631:
618:
616:
603:
602:
600:
599:
591:
589:
583:
582:
580:
579:
571:
569:
563:
562:
560:
559:
552:
544:
542:
536:
535:
533:
532:
524:
522:
516:
515:
513:
512:
504:
502:
496:
495:
493:
492:
484:
482:
476:
475:
473:
472:
464:
462:
456:
455:
453:
452:
444:
442:
431:
430:
428:
427:
419:
417:
411:
410:
408:
407:
384:
376:
375:
374:
371:
370:
366:
365:
363:
362:
353:
341:
330:
316:
314:
308:
307:
303:
302:
300:
299:
295:
293:
287:
286:
283:
277:
276:
271:
269:administration
263:
262:
260:
259:
257:
247:
245:
237:
236:
234:
233:
216:
199:
181:
179:
173:
172:
165:
159:
158:
151:
141:
140:
128:
124:
123:
120:
114:
113:
109:
108:
89:
88:
49:of the subject
47:worldwide view
42:
40:
33:
26:
24:
14:
13:
10:
9:
6:
4:
3:
2:
3256:
3245:
3242:
3240:
3239:Fish products
3237:
3235:
3232:
3230:
3227:
3225:
3222:
3220:
3217:
3215:
3212:
3210:
3207:
3206:
3204:
3194:
3184:
3180:
3163:
3161:
3158:
3157:
3155:
3152:
3149:
3146:
3144:
3141:
3140:
3136:
3130:
3127:
3125:
3122:
3120:
3117:
3115:
3112:
3110:
3107:
3105:
3102:
3100:
3097:
3095:
3092:
3090:
3087:
3085:
3082:
3080:
3077:
3075:
3072:
3070:
3067:
3065:
3062:
3060:
3057:
3056:
3054:
3050:
3044:
3041:
3039:
3036:
3034:
3031:
3029:
3026:
3024:
3021:
3019:
3016:
3014:
3011:
3009:
3006:
3004:
3001:
2999:
2996:
2995:
2993:
2989:
2979:
2976:
2975:
2973:
2970:
2966:
2962:
2958:
2952:
2949:
2947:
2944:
2942:
2939:
2937:
2934:
2933:
2931:
2928:
2924:
2920:
2914:
2911:
2909:
2906:
2904:
2901:
2899:
2896:
2894:
2891:
2890:
2888:
2885:
2881:
2877:
2867:
2864:
2863:
2861:
2857:
2851:
2848:
2846:
2843:
2841:
2838:
2836:
2833:
2831:
2828:
2826:
2823:
2821:
2818:
2816:
2813:
2811:
2808:
2806:
2803:
2801:
2798:
2796:
2793:
2791:
2788:
2786:
2783:
2782:
2780:
2778:
2774:
2771:
2768:
2767:PPAR agonists
2764:
2761:
2759:
2758:Blood vessels
2755:
2745:
2742:
2740:
2737:
2736:
2734:
2731:
2730:Thyromimetics
2727:
2721:
2718:
2717:
2715:
2712:
2708:
2704:
2698:
2695:
2693:
2690:
2688:
2685:
2684:
2682:
2679:
2675:
2671:
2665:
2662:
2660:
2657:
2655:
2652:
2650:
2647:
2645:
2642:
2640:
2637:
2636:
2634:
2631:
2627:
2622:
2616:
2613:
2611:
2608:
2606:
2603:
2601:
2598:
2596:
2593:
2591:
2588:
2586:
2583:
2581:
2578:
2576:
2573:
2572:
2570:
2567:
2563:
2559:
2555:
2552:
2550:
2546:
2536:
2532:
2528:
2527:Soluble fiber
2525:
2523:
2520:
2518:
2517:Colestyramine
2515:
2513:
2510:
2508:
2505:
2503:
2500:
2499:
2497:
2494:
2490:
2486:
2482:
2476:
2473:
2471:
2468:
2466:
2463:
2462:
2460:
2458:
2454:
2450:
2447:
2445:
2441:
2436:
2432:
2425:
2420:
2418:
2413:
2411:
2406:
2405:
2402:
2383:
2379:
2377:
2372:
2366:
2364:
2360:
2347:
2343:
2342:
2337:
2330:
2327:
2314:
2310:
2309:
2304:
2297:
2294:
2281:
2277:
2276:
2271:
2264:
2261:
2248:
2244:
2243:
2238:
2231:
2228:
2225:
2221:
2218:
2212:
2209:
2196:
2192:
2190:
2184:
2178:
2175:
2162:
2158:
2154:
2147:
2144:
2140:
2136:
2133:
2127:
2124:
2111:
2107:
2105:
2099:
2093:
2090:
2077:
2073:
2069:
2063:
2060:
2047:
2043:
2039:
2032:
2029:
2024:
2020:
2015:
2010:
2006:
2002:
1998:
1991:
1988:
1983:
1979:
1974:
1969:
1965:
1961:
1957:
1950:
1947:
1942:
1938:
1933:
1928:
1924:
1920:
1919:Diabetes Care
1916:
1914:
1908:
1902:
1899:
1894:
1890:
1885:
1880:
1876:
1872:
1868:
1864:
1860:
1853:
1850:
1845:
1841:
1836:
1831:
1827:
1823:
1819:
1815:
1811:
1804:
1801:
1788:
1784:
1780:
1774:
1771:
1758:
1754:
1752:
1746:
1740:
1737:
1724:
1720:
1716:
1710:
1707:
1694:
1690:
1686:
1680:
1677:
1674:
1670:
1666:
1661:
1658:
1645:
1641:
1637:
1631:
1628:
1615:
1611:
1605:
1602:
1597:
1593:
1588:
1583:
1578:
1573:
1569:
1565:
1561:
1554:
1551:
1546:
1542:
1538:
1534:
1530:
1526:
1522:
1518:
1511:
1509:
1505:
1500:
1496:
1491:
1486:
1482:
1478:
1474:
1470:
1463:
1461:
1457:
1444:
1440:
1436:
1430:
1427:
1414:
1410:
1406:
1400:
1397:
1384:
1380:
1378:
1372:
1366:
1363:
1350:
1346:
1342:
1337:
1332:
1328:
1324:
1320:
1313:
1311:
1309:
1307:
1303:
1299:
1298:public domain
1280:
1276:
1274:
1268:
1262:
1260:
1258:
1256:
1254:
1252:
1250:
1248:
1246:
1244:
1242:
1240:
1238:
1234:
1221:
1217:
1213:
1207:
1204:
1191:
1187:
1185:
1180:
1174:
1172:
1170:
1168:
1166:
1162:
1149:
1145:
1141:
1135:
1133:
1131:
1129:
1127:
1125:
1123:
1121:
1119:
1117:
1115:
1111:
1098:
1094:
1093:
1092:Health Canada
1088:
1082:
1079:
1066:
1062:
1058:
1052:
1050:
1046:
1039:
1037:
1035:
1031:
1023:
1018:
1016:
1012:
1008:
1005:
1001:
998:
994:
990:
985:
983:
982:off-label use
979:
975:
971:
963:
961:
959:
955:
951:
943:
941:
939:
935:
931:
927:
918:
916:
909:
907:
905:
904:bleeding time
901:
897:
889:
887:
881:Effectiveness
880:
875:
872:
869:
866:
865:
864:
858:
856:
853:
845:
839:
835:
833:
829:
821:
819:
813:
809:
805:
801:
798:
793:
789:
787:
783:
779:
775:
771:
767:
763:
754:
748:
739:
734:
730:
723:
714:
710:
703:
696:
692:
691:
689:
686:
681:
674:
672:
668:
647:
645:
641:
636:
628:
624:
620:
619:
617:
608:
604:
597:
596:ChEMBL2095209
593:
592:
590:
588:
584:
577:
573:
572:
570:
568:
564:
557:
553:
550:
546:
545:
543:
541:
537:
530:
526:
525:
523:
521:
517:
510:
506:
505:
503:
501:
497:
490:
486:
485:
483:
481:
477:
470:
466:
465:
463:
461:
457:
450:
446:
445:
443:
436:
432:
425:
421:
420:
418:
416:
412:
404:
400:
396:
392:
388:
383:
379:
372:
367:
361: Rx-only
354:
352:
342:
340:
331:
328:
318:
317:
315:
313:
309:
304:
297:
296:
294:
292:
288:
284:
282:
278:
275:
272:
270:
264:
258:
249:
248:
246:
244:
238:
231:
227:
217:
214:
209:
200:
197:
192:
183:
182:
180:
178:
174:
170:
166:
164:
160:
156:
152:
150:
146:
142:
133:
129:
125:
121:
119:
115:
112:Clinical data
110:
106:
101:
93:
85:
82:
74:
64:
60:
56:
50:
48:
41:
32:
31:
19:
3219:Ethyl esters
3214:Biochemistry
3129:Volanesorsen
2991:Combinations
2963:inhibitors (
2805:Clinofibrate
2800:Ciprofibrate
2709:inhibitors (
2676:inhibitors (
2659:Nicofuranose
2610:Rosuvastatin
2600:Pitavastatin
2580:Cerivastatin
2575:Atorvastatin
2386:. Retrieved
2374:
2350:. Retrieved
2339:
2329:
2317:. Retrieved
2306:
2296:
2284:. Retrieved
2273:
2263:
2251:. Retrieved
2240:
2230:
2211:
2199:. Retrieved
2186:
2177:
2165:. Retrieved
2146:
2130:CenterWatch
2126:
2114:. Retrieved
2101:
2092:
2080:. Retrieved
2071:
2062:
2050:. Retrieved
2041:
2031:
2004:
2000:
1990:
1963:
1959:
1949:
1922:
1918:
1912:
1901:
1866:
1862:
1852:
1817:
1813:
1803:
1791:. Retrieved
1782:
1773:
1761:. Retrieved
1748:
1739:
1727:. Retrieved
1723:the original
1718:
1709:
1697:. Retrieved
1688:
1679:
1660:
1648:. Retrieved
1639:
1630:
1618:. Retrieved
1614:the original
1604:
1567:
1563:
1553:
1520:
1516:
1480:
1476:
1447:. Retrieved
1438:
1429:
1417:. Retrieved
1408:
1399:
1387:. Retrieved
1374:
1365:
1353:. Retrieved
1349:the original
1326:
1322:
1283:. Retrieved
1270:
1224:. Retrieved
1215:
1206:
1194:. Retrieved
1182:
1152:. Retrieved
1143:
1101:. Retrieved
1090:
1081:
1069:. Retrieved
1060:
1027:
1024:Legal status
1013:
1009:
1006:
1002:
986:
967:
947:
922:
913:
910:Pharmacology
893:
890:Side effects
884:
862:
840:
836:
825:
822:Medical uses
794:
790:
782:dyslipidemia
773:
769:
765:
761:
760:
751:
402:
398:
394:
390:
386:
312:Legal status
306:Legal status
177:License data
92:
77:
68:
44:
3229:Polyolefins
3150:from market
3109:Policosanol
3084:Lapaquistat
3064:Azacosterol
2941:Bococizumab
2913:Torcetrapib
2908:Obicetrapib
2903:Evacetrapib
2898:Dalcetrapib
2893:Anacetrapib
2845:Ronifibrate
2840:Pemafibrate
2830:Gemfibrozil
2825:Fenofibrate
2790:Bezafibrate
2697:Mitratapide
2687:Dirlotapide
2615:Simvastatin
2605:Pravastatin
2585:Fluvastatin
2535:glucomannan
2502:Colesevelam
2352:21 December
2319:21 December
2001:Circulation
1869:(1): 2329.
1729:15 December
1719:CenterWatch
1523:(7): 7–18.
1285:21 December
678: g·mol
576:CHEBI:84883
369:Identifiers
163:MedlinePlus
127:Other names
118:Trade names
3203:Categories
3124:Triparanol
3099:Mipomersen
3079:Darapladib
3074:Benfluorex
3069:Azalanstat
2978:Evinacumab
2951:Inclisiran
2946:Evolocumab
2936:Alirocumab
2850:Simfibrate
2820:Etofibrate
2815:Clofibride
2810:Clofibrate
2744:Resmetirom
2692:Lomitapide
2654:Niceritrol
2595:Mevastatin
2590:Lovastatin
2512:Colestipol
2507:Colestilan
2470:Hyzetimibe
2388:1 February
2201:15 January
2167:1 November
2116:15 January
2082:15 January
1793:15 January
1763:15 January
1699:2 February
1650:15 January
1355:16 January
1154:15 January
1040:References
940:in blood.
778:medication
683:3D model (
671:Molar mass
529:6GC8A4PAYH
500:ChemSpider
460:IUPHAR/BPS
424:86227-47-6
415:CAS Number
378:IUPAC name
281:Drug class
27:Medication
3160:Phase III
3148:Withdrawn
2835:Nafenopin
2522:Colextran
2475:SCH-48461
2465:Ezetimibe
2253:27 August
2072:Drugs.com
1783:Drugs.com
1570:(1): 23.
1449:7 October
1419:7 October
1389:15 August
1323:P & T
1057:"Vazkepa"
944:Chemistry
834:therapy.
828:indicated
267:Routes of
241:Pregnancy
155:Monograph
149:Drugs.com
71:June 2021
59:talk page
18:Ethyl-EPA
3193:Medicine
3119:Tiadenol
3114:Probucol
3094:Meglutol
2866:GW501516
2777:Fibrates
2639:Acipimox
2531:psyllium
2529:such as
2444:GI tract
2382:Archived
2346:Archived
2313:Archived
2280:Archived
2247:Archived
2220:Archived
2195:Archived
2161:Archived
2135:Archived
2110:Archived
2076:Archived
2046:Archived
2023:31422671
1982:28437620
1941:31862748
1893:33888689
1844:31567003
1787:Archived
1757:Archived
1693:Archived
1689:DailyMed
1669:Archived
1644:Archived
1640:DailyMed
1596:28137294
1545:12524547
1537:25387209
1499:26699442
1443:Archived
1439:ClinCalc
1413:Archived
1409:ClinCalc
1383:Archived
1345:26681905
1279:Archived
1220:Archived
1190:Archived
1148:Archived
1144:DailyMed
1097:Archived
1071:29 April
1065:Archived
808:fish oil
480:DrugBank
385:Ethyl (5
291:ATC code
274:By mouth
256: B1
243:category
208:DailyMed
53:You may
2961:ANGPTL3
2558:Statins
2052:1 April
1884:8062567
1835:6806028
1620:1 April
1587:5282870
1336:4671468
1226:3 March
964:History
915:liver.
774:Vascepa
676:330.512
644:Formula
509:8007147
489:DB08887
449:9831415
435:PubChem
337::
230:Vascepa
228::
210::
193::
169:a613024
3179:Portal
3143:WHO-EM
2859:Others
2732:(VLDL)
2649:Niacin
2489:resins
2457:NPC1L1
2286:17 May
2242:Forbes
2021:
1980:
1939:
1891:
1881:
1842:
1832:
1594:
1584:
1543:
1535:
1497:
1343:
1333:
1196:7 July
1103:29 May
832:statin
816:
709:SMILES
587:ChEMBL
556:C16184
549:D01892
351:℞-only
349:
339:℞-only
325:
223:
206:
196:by INN
189:
3052:Other
2769:(LDL)
2549:Liver
2378:(EMA)
2191:(FDA)
2187:U.S.
2106:(FDA)
2102:U.S.
1753:(FDA)
1749:U.S.
1541:S2CID
1379:(FDA)
1375:U.S.
1275:(FDA)
1271:U.S.
1186:(EMA)
950:ester
852:LDL-C
766:E-EPA
729:InChI
685:JSmol
567:ChEBI
61:, or
2678:VLDL
2674:MTTP
2628:and
2533:and
2390:2021
2354:2019
2321:2019
2288:2017
2255:2017
2203:2020
2169:2021
2118:2020
2084:2020
2054:2016
2019:PMID
1978:PMID
1937:PMID
1889:PMID
1840:PMID
1795:2020
1765:2020
1731:2014
1701:2020
1652:2020
1622:2016
1592:PMID
1533:PMID
1495:PMID
1451:2022
1421:2022
1391:2020
1357:2020
1341:PMID
1287:2019
1228:2023
1198:2021
1156:2020
1105:2022
1073:2023
784:and
540:KEGG
520:UNII
469:7441
298:None
145:AHFS
132:USAN
2969:HDL
2965:LDL
2927:LDL
2884:HDL
2711:LDL
2630:LDL
2626:HDL
2566:LDL
2493:LDL
2435:C10
2009:doi
2005:140
1968:doi
1927:doi
1879:PMC
1871:doi
1830:PMC
1822:doi
1582:PMC
1572:doi
1525:doi
1521:126
1485:doi
1331:PMC
952:of
612:EPA
439:CID
401:,17
397:,14
393:,11
226:FDA
191:EMA
3205::
3156::
2564:,
2455:,
2373:.
2362:^
2344:.
2338:.
2311:.
2305:.
2278:.
2272:.
2245:.
2239:.
2185:.
2159:.
2155:.
2100:.
2070:.
2044:.
2040:.
2017:.
2003:.
1999:.
1976:.
1964:23
1962:.
1958:.
1935:.
1923:43
1921:.
1917:.
1887:.
1877:.
1867:12
1865:.
1861:.
1838:.
1828:.
1816:.
1812:.
1781:.
1747:.
1717:.
1691:.
1687:.
1638:.
1590:.
1580:.
1568:16
1566:.
1562:.
1539:.
1531:.
1519:.
1507:^
1493:.
1479:.
1475:.
1459:^
1441:.
1437:.
1411:.
1407:.
1381:.
1373:.
1339:.
1327:40
1325:.
1321:.
1305:^
1269:.
1236:^
1218:.
1214:.
1181:.
1164:^
1142:.
1113:^
1089:.
1059:.
1048:^
960:.
768:,
658:34
652:22
389:,8
357:EU
345:US
334:CA
327:S4
321:AU
252:AU
220:US
203:US
186:EU
136:US
3181::
2971:)
2967:/
2929:)
2925:(
2886:)
2882:(
2713:)
2680:)
2632:)
2568:)
2560:(
2495:)
2491:(
2487:/
2437:)
2433:(
2423:e
2416:t
2409:v
2392:.
2356:.
2323:.
2290:.
2257:.
2205:.
2171:.
2120:.
2086:.
2056:.
2025:.
2011::
1984:.
1970::
1943:.
1929::
1915:"
1895:.
1873::
1846:.
1824::
1818:8
1797:.
1767:.
1733:.
1703:.
1654:.
1624:.
1598:.
1574::
1547:.
1527::
1501:.
1487::
1481:9
1453:.
1423:.
1393:.
1359:.
1300:.
1289:.
1230:.
1200:.
1158:.
1107:.
1075:.
991:(
764:(
687:)
664:2
661:O
655:H
649:C
614:)
610:(
403:Z
399:Z
395:Z
391:Z
387:Z
359::
347::
323::
254::
147:/
139:)
84:)
78:(
73:)
69:(
51:.
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
